Teva Pharmaceutical Industries (NYSE:TEVA) Earns Outperform Rating from Analysts at Oppenheimer

by · The Markets Daily

Oppenheimer started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) in a report issued on Wednesday, Benzinga reports. The brokerage set an “outperform” rating and a $50.00 price target on the stock. Oppenheimer’s price objective suggests a potential upside of 26.40% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on TEVA. Weiss Ratings cut shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Leerink Partners assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $43.73.

Check Out Our Latest Report on TEVA

Teva Pharmaceutical Industries Trading Down 1.3%

Shares of TEVA stock opened at $39.56 on Wednesday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The stock has a fifty day simple moving average of $35.73 and a two-hundred day simple moving average of $33.65. The firm has a market capitalization of $46.10 billion, a PE ratio of 65.93, a PEG ratio of 4.99 and a beta of 0.87. Teva Pharmaceutical Industries has a 52-week low of $18.21 and a 52-week high of $40.79.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. On average, analysts predict that Teva Pharmaceutical Industries will post 1.94 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This represents a 46.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 374,959 shares of company stock worth $14,644,285 in the last 90 days. 0.54% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares during the period. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at approximately $43,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $45,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.

Read More